Clinical Trial Update: Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VRC07-523LS, CAP256V2LS, and Vesatolimod in early ART-treated women with HIV-1 infection; the study is completed with results posted Ja…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CAP256V2LS
• VRC07-523LS
• Vesatolimod (vesatolimod)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1-infection | Phase 2 | Status: COMPLETED | Results posted: 2026-01-16